

10/722,085

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 6 SEP 27 STANDARDS will no longer be available on STN
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN
NEWS 8 OCT 28 KOREAPAT now available on STN
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current
search transcripts to be affected by CERAB, COMPUAB, ELCOM,
and SOLIDSTATE reloads

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:51:13 ON 23 NOV 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:51:23 ON 23 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

10/722,085

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 NOV 2004 HIGHEST RN 786612-66-6
DICTIONARY FILE UPDATES: 22 NOV 2004 HIGHEST RN 786612-66-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10722085.str



chain nodes :

19 20 21 22 23 24 25 27 28 29 31 32

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

2-19 5-14 9-17 12-23 19-20 19-21 20-22 21-31 22-32 23-24 23-25 24-27
25-29 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17

exact/norm bonds :

2-19 5-14 9-17 12-23 13-14 13-17 14-15 15-16 16-17 19-20 19-21 20-22
21-31 22-32 23-24 23-25 24-27 25-29 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:O,S,CH2,NH

G2:H,Cb,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
31:CLASS 32:CLASS

10/722,085

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\107220851.str



chain nodes :

19 20 21 22 23 24 25 27 28 29 31 32

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

2-19 5-14 9-17 12-23 19-20 19-21 20-22 21-31 22-32 23-24 23-25 24-27
25-29 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17

exact/norm bonds :

2-19 5-14 9-17 12-23 13-14 13-17 14-15 15-16 16-17 19-20 19-21 20-22
21-31 22-32 23-24 23-25 24-27 25-29 27-28

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 : 13 :

G1:O,S,CH2,NH

G2:H,Cb,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
31:CLASS 32:CLASS

L2 STRUCTURE UPLOADED

=> s 12

SAMPLE SEARCH INITIATED 17:52:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

10/722,085

100.0% PROCESSED 6 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6 TO 266
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L2


=> s 12 ful
FULL SEARCH INITIATED 17:52:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 131 TO ITERATE

100.0% PROCESSED 131 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

L4 18 SEA SSS FUL L2

=> d scan

L4 18 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-butoxy- (9CI)
MF C26 H32 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	156.26	156.47

FILE 'CAPLUS' ENTERED AT 17:53:15 ON 23 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

10/722,085

strictly prohibited.

FILE COVERS 1907 - 23 Nov 2004 VOL 141 ISS 22
FILE LAST UPDATED: 22 Nov 2004 (20041122/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> sl4

SL4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l4

L5 24 L4

=> s l5 and(process or syntheses? or make or made or prepar? or making)

2015736 PROCESS

1337191 PROCESSES

2994738 PROCESS

(PROCESS OR PROCESSES)

1408419 SYNTHES?

199908 MAKE

154085 MAKES

344179 MAKE

(MAKE OR MAKES)

1122812 MADE

24 MADES

1122832 MADE

(MADE OR MADES)

1507696 PREPAR?

113402 PREP

2009 PREPS

115210 PREP

(PREP OR PREPS)

1899226 PREPD

21 PREPDS

1899241 PREPD

(PREPD OR PREPDS)

104072 PREPG

12 PREPGS

104083 PREPG

(PREPG OR PREPGS)

2524098 PREPN

197129 PREPNS

2673564 PREPN

(PREPN OR PREPNS)

4431116 PREPAR?

(PREPAR? OR PREP OR PREPD OR PREPG OR PREPN)

237241 MAKING

29 MAKINGS

237264 MAKING

(MAKING OR MAKINGS)


L6 16 L5 AND(PROCESS OR SYNTHES? OR MAKE OR MADE OR PREPAR? OR MAKING)

=> d l6 ibib hitstr abs 1-16


L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

10/722,085

ACCESSION NUMBER: 2004:566930 CAPLUS
DOCUMENT NUMBER: 141:199478
TITLE: O-Alkoxyamidine Prodrugs of Furamidine: In Vitro
Transport and Microsomal Metabolism as Indicators of
in Vivo Efficacy in a Mouse Model of Trypanosoma
brucei rhodesiense Infection
AUTHOR(S): Ansele, John H.; Anbazhagan, Mariappan; Brun, Reto;
Easterbrook, Judy D.; Hall, James Edwin; Boykin, David
W.
CORPORATE SOURCE: Division of Drug Delivery and Disposition School of
Pharmacy, University of North Carolina at Chapel Hill,
Chapel Hill, NC, 27599-7360, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(17),
4335-4338
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 475976-08-0 743438-64-4 743438-66-6
743438-67-7 743438-68-8
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL
(Biological study)
(in vitro transport and microsomal metabolism of O-alkoxyamidine prodrugs
of furamidine as indicators of in vivo efficacy in mouse model of
Trypanosoma brucei rhodesiense infection)
RN 475976-08-0 CAPLUS
CN Benzenecarboximidamide, 4-[5-[4-[(hydroxyamino)iminomethyl]phenyl]-2-
furanyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 743438-64-4 CAPLUS
CN Benzenecarboximidamide, 4-[5-[4-[(ethoxyamino)iminomethyl]phenyl]-2-
furanyl]-N-(2-hydroxyethoxy)- (9CI) (CA INDEX NAME)




RN 743438-66-6 CAPLUS
CN Benzenecarboximidamide, 4-[5-[4-[(ethoxyamino)iminomethyl]phenyl]-2-
furanyl]-N-hydroxy- (9CI) (CA INDEX NAME)

10/722,085




RN 743438-67-7 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-(2-hydroxyethoxy)- (9CI)
(CA INDEX NAME)



RN 743438-68-8 CAPLUS

CN Benzenecarboximidamide, N-hydroxy-4-[5-[4-[[2-hydroxyethoxy) amino]iminomethyl]phenyl]-2-furanyl]- (9CI) (CA INDEX NAME)




IT 186953-56-0P 186953-57-1P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(in vitro transport and microsomal metabolism of O-alkoxyamidine prodrugs of furamidine as indicators of in vivo efficacy in mouse model of Trypanosoma brucei rhodesiense infection)

RN 186953-56-0 CAPLUS


CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA INDEX NAME)



RN 186953-57-1 CAPLUS

10/722,085

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-ethoxy- (9CI) (CA INDEX NAME)




IT 186953-55-9P 582300-97-8P 743438-61-1P
743438-62-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(in vitro transport and microsomal metabolism of O-alkoxyamidine prodrugs of furamidine as indicators of in vivo efficacy in mouse model of Trypanosoma brucei rhodesiense infection)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)




RN 582300-97-8 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-propoxy- (9CI) (CA INDEX NAME)




RN 743438-61-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 743438-62-2 CAPLUS
 CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-butoxy- (9CI) (CA INDEX NAME)



AB Five O-alkoxyamidine analogs of the prodrug 2,5-bis[4-methoxyamidinophenyl]furan were **synthesized** and evaluated against Trypanosoma brucei rhodesiense in the STIB900 mouse model by oral administration. The observed in vivo activity of these prodrugs demonstrates that compds. with an O-methoxyamidine or O-ethoxyamidine group effectively cured all trypanosome-infected mice, whereas prodrugs with larger side-chains did not completely cure the mice. Permeability across Caco-2 cell monolayers and microsomal metabolism were used to identify the underlying mechanisms of prodrug efficacy.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:493958 CAPLUS

DOCUMENT NUMBER: 141:54184

TITLE: Cross-coupling **process** and palladium catalysts for the **synthesis** of bis-aryl diamidoxime compounds

INVENTOR(S): Boykin, David W.; Anbazhagan, Mariappan; Tidwell, Richard R.

PATENT ASSIGNEE(S): University of North Carolina at Chapel Hill, USA; Georgia State University Research Foundation, Inc.

SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004051217	A2	20040617	WO 2003-US37788	20031125
WO 2004051217	A3	20040708		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

10/722,085

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM,
AZ, BY, KG, KZ

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 2004127721

A1

20040701

US 2003-722085

20031125

PRIORITY APPLN. INFO.:

US 2002-429823P

P 20021127

OTHER SOURCE(S):

CASREACT 141:54184; MARPAT 141:54184


IT 186953-55-9P 186953-56-0P 186953-57-1P

582300-97-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(cross-coupling **process** and palladium catalysts for the
synthesis of bis-aryl diamidoxime compds.)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA
INDEX NAME)




RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA
INDEX NAME)



RN 186953-57-1 CAPLUS


CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-ethoxy- (9CI) (CA INDEX
NAME)



RN 582300-97-8 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-propoxy- (9CI) (CA

INDEX NAME)



AB Bisaryl diamidoxime compds., such as 2,5-bis[4-hydroxy- and 4-O-alkylamidinophenyl]furans are **prepared** in high yield and selectivity from the one-step cross-coupling reaction of 2,5-bis(trialkylstannyl)heterocyclic compds. [e.g., 2,5-(bistributylstannyl)furan] with p-bromobenzamidoximes (e.g., p-bromobenzamidoxime) and their amidoxime ethers in the presence of a palladium catalyst [e.g., tetrakis(triphenylphosphine)palladium].

L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:991295 CAPLUS

DOCUMENT NUMBER: 140:35966

TITLE: Amidine derivatives for treating amyloidosis and neurodegenerative diseases

INVENTOR(S): Chalifour, Robert J.; Kong, Xianqi; Wu, Xinfu; Lu, Wenshuo; Tidwell, Richard R.; Boykin, David

PATENT ASSIGNEE(S): University of North Carolina At Chapel Hill, USA; Georgia State University Research Foundation, Inc.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103598	A2	20031218	WO 2003-US17992	20030609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004147531	A1	20040729	US 2003-731463	20031205
PRIORITY APPLN. INFO.:			US 2002-387001P	P 20020607
			US 2001-316761P	P 20010831
			US 2002-234643	A1 20020903

IT 186953-56-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**preparation** of amidine derivs. for treating amyloidosis and neurodegenerative diseases)

RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA

INDEX NAME)



AB The present invention relates to the use of amidine compds. in the treatment of amyloid related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compds. for use according to the invention are those according to the following Formulas, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited.

L6 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:949264 CAPLUS

DOCUMENT NUMBER: 140:93762

TITLE: Direct conversion of amidoximes to amidines via transfer hydrogenation

AUTHOR(S): Anbazhagan, Mariappan; Boykin, David W.; Stephens, Chad E.

CORPORATE SOURCE: Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA

SOURCE: Synthesis (2003), (16), 2467-2469

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 140:93762

IT 186953-55-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(conversion of amidoximes to amidines via transfer hydrogenation)

RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)



AB Amidoximes, O-alkylamidoximes, and O-acylamidoximes are directly converted to amidines by reaction with ammonium formate and Pd/C in HOAc.


REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:513253 CAPLUS

10/722,085

DOCUMENT NUMBER: 139:390750
TITLE: Detection of inhibition of bovine viral diarrhea virus
by aromatic cationic molecules
AUTHOR(S): Givens, M. Daniel; Dykstra, Christine C.; Brock, Kenny
V.; Stringfellow, David A.; Kumar, Arvind; Stephens,
Chad E.; Goker, Hakan; Boykin, David W.
CORPORATE SOURCE: Department of Pathobiology, College of Veterinary
Medicine, Auburn University, Auburn, AL, 36849, USA
SOURCE: Antimicrobial Agents and Chemotherapy (2003), 47(7),
2223-2230
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:390750
IT 186953-56-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(inhibition of bovine viral diarrhea virus by aromatic cationic mols.)
RN 186953-56-0 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA
INDEX NAME)



AB Bovine viral diarrhea virus (BVDV) is an economically significant pathogen
of cattle and a problematic contaminant in the laboratory BVDV is often used
as
an in vitro model for hepatitis C virus during drug discovery efforts.
Aromatic dicationic mols. have exhibited inhibitory activity against several
RNA viruses. Thus, the purpose of this research was to develop and apply
a method for screening the aromatic cationic compds. for in vitro
cytotoxicity and activity against a noncytopathic strain of BVDV. The
screening method evaluated the concentration of BVDV in medium and cell lysates
after 72 h of cell culture in the presence of either a 25 or 5 μ M
concentration of the test compound Five of 93 screened compds. were selected
for
further determination of inhibitory (90 and 50%) and cytotoxic (50 and 10%)
concentration
endpoints. The screening method identified compds. that exhibited
inhibition of BVDV at nanomolar concns. while exhibiting no cytotoxicity
at 25 μ M concns. The leading compds. require further investigation to
determine their mechanism of action, in vivo activity, and specific activity
against hepatitis C virus.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 2003:416455 CAPLUS

DOCUMENT NUMBER: 139:197315


TITLE: A facile **synthesis** of the prodrug
2,5-bis(4-O-methoxyamidinophenyl)furan and analogs

10/722,085


AUTHOR(S): Anbazhagan, Mariappan; Boykin, David W.
CORPORATE SOURCE: Department of Chemistry, Georgia State University,
Atlanta, GA, 30303, USA
SOURCE: Heterocyclic Communications (2003), 9(2), 117-118
CODEN: HCOMEX; ISSN: 0793-0283
PUBLISHER: Freund Publishing House Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:197315
IT 186953-55-9P 186953-56-0P 186953-57-1P
582300-97-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(**synthesis** of 2,5-bis(4-O-methoxyamidinophenyl)furan and
analogues)
RN 186953-55-9 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA
INDEX NAME)




RN 186953-56-0 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA
INDEX NAME)



RN 186953-57-1 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-ethoxy- (9CI) (CA INDEX
NAME)



RN 582300-97-8 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-propoxy- (9CI) (CA
INDEX NAME)



AB A convenient **synthesis** of the prodrug 2,5-bis(4-o-methoxyamidinophenyl)furan and analogs using 2,5-bis(tri-n-butylstannyl)furan and palladium catalyzed cross-coupling reactions is described. For example, refluxing 2,5-bis(tri-n-butylstannyl)furan with O-propyl-p-bromobenzamidoxime in dioxane in the presence of tetrakis(triphenylphosphine)palladium for 16 h gave 70% 2,5-bis(4-O-propoxyamidinophenyl)furan.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:338839 CAPLUS

DOCUMENT NUMBER: 139:230527

TITLE: **Synthesis** of metabolites of the prodrug 2,5-bis(4-o-methoxyamidinophenyl)furan

AUTHOR(S): Anbazhagan, Mariappan; Saulter, Janelle Y.; Hall, James E.; Boykin, David W.

CORPORATE SOURCE: Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA

SOURCE: Heterocycles (2003), 60(5), 1133-1145
CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 139:230527

IT **475976-08-0P**, 4-[5-[4-[(Hydroxyamino)iminomethyl]phenyl]-2-furanyl]-N-methoxybenzenecarboximidamide

RL: SPN (Synthetic preparation); PREP (Preparation)
(4,4'-(2,5-furandiyl)bis[N-methoxybenzenecarboximidamide] metabolite; **preparation** of metabolites of prodrug [4,4'-(2,5-furandiyl)bis[N-methoxybenzenecarboximidamide]])

RN 475976-08-0 CAPLUS

CN Benzenecarboximidamide, 4-[5-[4-[(hydroxyamino)iminomethyl]phenyl]-2-furanyl]-N-methoxy- (9CI) (CA INDEX NAME)




IT **591735-85-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(**preparation** of metabolites of prodrug [4,4'-(2,5-furandiyl)bis[N-methoxybenzenecarboximidamide]])

10/722,085

RN 591735-85-2 CAPLUS
CN Benzenecarboximidamide, 4-[5-[4-[[[acetyloxy]aminomethyl]phenyl]-2-furanyl]-N-methoxy- (9CI) (CA INDEX NAME)



IT **186953-56-0DP**, 4,4'-(2,5-Furandiyl)bis[N-methoxybenzenecarboximidamide], metabolites
RL: SPN (Synthetic preparation); PREP (Preparation)
(**preparation** of metabolites of prodrug [4,4'-(2,5-furandiyl)bis[N-methoxybenzenecarboximidamide]])
RN 186953-56-0 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA INDEX NAME)



AB The **synthesis** of three metabolites of the prodrug 2,5-bis(4-O-methoxyamidinophenyl)furan [i.e., 4,4'-(2,5-furandiyl)bis[N-methoxybenzenecarboximidamide]] was reported. Metabolites included 4-[5-[4-[(hydroxyamino)iminomethyl]phenyl]-2-furanyl]-N-methoxybenzenecarboximidamide, 4-[5-[4-[(methoxyamino)iminomethyl]phenyl]-2-furanyl]benzenecarboximidamide and 4-[5-[4-[(hydroxyamino)iminomethyl]phenyl]-2-furanyl]benzenecarboximidamide. The key step in each of the **syntheses** involves the Heck reaction.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:173414 CAPLUS

DOCUMENT NUMBER: 138:215350

TITLE: Amidine derivatives for treating amyloid-related diseases

INVENTOR(S): Chalifour, Robert J.; Kong, Xianqi; Wu, Xinfu; Lu, Wenshuo

PATENT ASSIGNEE(S): Neurochem Inc., Can.

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 2003017994 A1 20030306 WO 2002-CA1353 20020903 ✓
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG
 US 2004006092 A1 20040108 US 2002-234643 20020903
 EP 1420773 A1 20040526 EP 2002-758012 20020903
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 BR 2002012078 A 20040928 BR 2002-12078 20020903
 US 2004147531 A1 20040729 US 2003-731463 20031205
 PRIORITY APPLN. INFO.:
 US 2001-316761P P 20010831
 US 2002-387001P P 20020607
 US 2002-234643 A1 20020903
 WO 2002-CA1353 W 20020903


OTHER SOURCE(S): MARPAT 138:215350

IT 186953-56-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (amidine derivs. for treating amyloid-related diseases)

RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA
 INDEX NAME)



AB The invention discloses the use of amidine compds. in the treatment of amyloid-related diseases (e.g. Alzheimer's disease, Down's syndrome, type II diabetes). In particular, the invention discloses a method for treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. The compds. of the invention (Markush included) are such that, when administered, reduce or inhibit amyloid fibril formation, neurodegeneration, or cellular toxicity. Compound **preparation** is described.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:146280 CAPLUS

DOCUMENT NUMBER: 136:321920

TITLE: Antileishmanial activities of several classes of aromatic dications

AUTHOR(S): Brendle, James J.; Outlaw, Abram; Kumar, Arvind;

10/722,085

Boykin, David W.; Patrick, Donald A.; Tidwell, Richard R.; Werbovetz, Karl A.

CORPORATE SOURCE:

Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA

SOURCE:

Antimicrobial Agents and Chemotherapy (2002), 46(3), 797-807

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER:

American Society for Microbiology

DOCUMENT TYPE:

Journal

LANGUAGE:


English

IT 186953-55-9 186953-56-0

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antileishmanial activities of several classes of aromatic dications)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)




RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA INDEX NAME)



GI



AB Aromatic dicationic mols. possess impressive activity against a broad spectrum of microbial pathogens, including *Pneumocystis carinii*,

Cryptosporidium parvum, and *Candida albicans*. In this work, 58 aromatic cations were examined for inhibitory activity against axenic amastigote-like *Leishmania donovani* parasites. In general, the most potent of the compds. were substituted di-Ph furan and thiophene dications.

2,5-Bis-(4-amidinophenyl)thiophene (I) was the most active compound. This agent displayed a 50% inhibitory concentration (IC₅₀) of $0.42 \pm 0.08 \mu\text{M}$ against *L. donovani* and an in vitro antileishmanial potency 6.2-fold greater than that of the clin. antileishmanial dication pentamidine and was 155-fold more toxic to the parasites than to a mouse macrophage cell line. 2,4-Bis-(4-amidinophenyl)furan (II) was twice as active as pentamidine (IC₅₀, $1.30 \pm 0.21 \mu\text{M}$), while 2,5-bis-(4-amidinophenyl)furan and pentamidine were essentially equipotent in our in vitro antileishmanial assay. Carbazoles, dibenzofurans, dibenzothiophenes, and benzimidazoles containing amidine or substituted amidine groups were generally less active than the di-Ph furans and thiophenes. In all cases, aromatic dications possessing strong antileishmanial activity were several-fold more toxic to the parasites than to a cultured mouse macrophage cell line. These structure-activity relationships demonstrate the potent antileishmanial activity of several aromatic dications and provide valuable information for the future design and **synthesis** of more potent antiparasitic agents.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:151106 CAPLUS

DOCUMENT NUMBER: 134:326363

TITLE: **Synthesis** of deuterium-labeled 2,5-bis(4-amidinophenyl)furan, 2,5-bis[4-(methoxyamidino)phenyl]furan, and 2,7-diamidinocarbazole

AUTHOR(S): Stephens, Chad E.; Patrick, Donald A.; Chen, Heidi; Tidwell, Richard R.; Boykin, David W.

CORPORATE SOURCE: Department of Chemistry, Georgia State University, Atlanta, GA, 30303, USA

SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (2001), 44(3), 197-208
CODEN: JLCRD4; ISSN: 0362-4803

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 134:326363

IT 336786-82-4P 336786-93-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(**preparation** of deuterium-labeled bis(amidinophenyl)furan, bis[(methoxyamidino)phenyl]furan, and diamidinocarbazole)

RN 336786-82-4 CAPLUS

CN Benzene-2,3,5,6-d₄-carboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy-(9CI) (CA INDEX NAME)




10/722,085

RN 336786-93-7 CAPLUS
CN Benzene-2,3,5,6-d4-carboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy-,
(2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 336786-82-4
CMF C20 H12 D8 N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



AB The **syntheses** of 2,5-bis(4-amidinophenyl)furan-d8 and 2,5-bis[4-(methoxyamidino)phenyl]furan-d8 from bromobenzene-d5 in six steps, and of 2,7-diamidinocarbazole-d6 from biphenyl-d10 in five steps, are described.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:50472 CAPLUS
DOCUMENT NUMBER: 134:120935
TITLE: Prodrugs for antimicrobial amidines
INVENTOR(S): Boykin, David W.; Rahmathullah, M. Syed; Tidwell, Richard R.; Hall, James E.
PATENT ASSIGNEE(S): University of North Carolina At Chapel Hill, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001003685	A2	20010118	WO 2000-US18499	20000706
WO 2001003685	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2377902	AA	20010118	CA 2000-2377902	20000706
EP 1242059	A2	20020925	EP 2000-950293	20000706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003504329	T2	20030204	JP 2001-508966	20000706
US 6486200	B1	20021126	US 2000-612138	20000707
US 2002019437	A1	20020214	US 2001-918787	20010731
US 6503940	B2	20030107		
US 2003092755	A1	20030515	US 2002-208947	20020730
US 6649652	B2	20031118		

PRIORITY APPLN. INFO.:

US 1999-142826P	P	19990708
WO 2000-US18499	W	20000706
US 2000-612138	A3	20000707
US 2001-918787	B3	20010731


OTHER SOURCE(S): MARPAT 134:120935

IT 247032-19-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prodrugs for antimicrobial amidines)

RN 247032-19-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-[(ethoxycarbonyl)oxy]- (9CI) (CA INDEX NAME)




IT 186953-55-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prodrugs for antimicrobial amidines)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)



10/722,085

GI



AB A methods of treating an infection comprises administering a therapeutically effective amount of a bis(amidinophenyl)furan. E.g., I was **prepared** along with 10 other similar compds. and showed in vivo activity against *Pneumocystis carinii*.

L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:562085 CAPLUS

DOCUMENT NUMBER: 131:299327

TITLE: Prodrugs for Amidines: **Synthesis** and Anti-*Pneumocystis carinii* Activity of Carbamates of 2,5-Bis(4-amidinophenyl)furan

AUTHOR(S): Rahmathullah, Syed M.; Hall, James Edwin; Bender, Brendan C.; McCurdy, Donald R.; Tidwell, Richard R.; Boykin, David W.

CORPORATE SOURCE: Department of Chemistry and Center for Biotechnology and Drug Design, Georgia State University, Atlanta, GA, 30303, USA

SOURCE: Journal of Medicinal Chemistry (1999), 42(19), 3994-4000

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 131:299327


IT **247032-19-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(**preparation** and anti-*Pneumocystis carinii* activity of carbamates of bis(amidinophenyl)furan **prepared** from aryl alkyl and diaryl carbonates)

RN 247032-19-5 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-[(ethoxycarbonyl)oxy]- (9CI) (CA INDEX NAME)




10/722,085

IT 186953-55-9


RL: RCT (Reactant); RACT (Reactant or reagent)
(**preparation** and anti-Pneumocystis carinii activity of carbamates
of bis(amidinophenyl)furan **prepared** from aryl alkyl and diaryl
carbonates)

RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA
INDEX NAME)



GI



AB **Syntheses** of several carbamate analogs of 2,5-bis(4-amidinophenyl)furan (I, R = H) under mild conditions and their evaluation as prodrugs against Pneumocystis carinii pneumonia (PCP) in an immunosuppressed rat model are described. Thus, nine new bis(carbamates) of bis(amidine) I [R = MeO₂C (II), Cl₃CCH₂O₂C (III), EtSCO (IV), PhCH₂O₂C (V), (4-methyl-2-oxo-1,3-dioxol-4-en-5-yl)methoxycarbonyl (VI), PhO₂C (VII), 4-FC₆H₄O₂C (VIII), 4-MeOC₆H₄O₂C (IX), AcOCHMeO₂C (X)] and a bis(carbonate) [R = EtOC(O)O (XI)] have been **synthesized** and evaluated. The in vivo results show that VIII and IX had the best anti-PCP activity by both i.v. and oral administration. Compds. III-VII were also more active than the parent drug I on oral administration. The acute toxicity usually exhibited by the parent amidine I at 22 μ mol/kg/day on i.v. administration has been significantly reduced by the prodrug modifications, with the exception of compound X which exhibited some toxicity. The **syntheses** of several aryl alkyl and diaryl carbonates as efficient reagents for the **preparation** of carbamate derivs. from bis(arylamidines) are also described.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:785675 CAPLUS

DOCUMENT NUMBER: 130:32999

TITLE: Benzamidoxime prodrugs as antipneumocystic agents

INVENTOR(S): Hall, James E.; Tidwell, Richard R.; Boykin, David W.

PATENT ASSIGNEE(S): Georgia State University Research Foundation Inc.,

USA; The University of North Carolina At Chapel Hill

SOURCE: U.S., 17 pp., Cont.-in-part of U.S. 5,723,495.

CODEN: USXXAM

10/722,085

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5843980	A	19981201	US 1996-751171	19961115
US 5723495	A	19980303	US 1995-558716	19951116
CA 2237650	AA	19970522	CA 1996-2237650	19961115
US 6025398	A	20000215	US 1998-127317	19980731
US 6214883	B1	20010410	US 2000-477390	20000104
AU 764937	B2	20030904	AU 2000-62473	20001004
US 2001044468	A1	20011122	US 2001-759664	20010112
US 6423737	B2	20020723		

PRIORITY APPLN. INFO.:

US 1995-558716	A2	19951116
AU 1997-11605	A3	19961115
US 1996-751171	A3	19961115
US 1998-127317	A3	19980731
US 2000-477390	A3	20000104


OTHER SOURCE(S): MARPAT 130:32999

IT 186953-55-9P 186953-56-0P 186953-57-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamidoxime prodrugs as antipneumocystic agents)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)




RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA INDEX NAME)




RN 186953-57-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-ethoxy- (9CI) (CA INDEX NAME)



GI



AB A method of treating *Pneumocystis carinii* pneumonia in a subject in need of such treatment is disclosed. The method comprises orally administering to the subject bis-benzamidoximes, such as I, which exhibited significant activity in infected rats (the anti-*Pneumocystis* value was expressed in percent of lung cysts in the treatment group vs. control group). The method of the present invention may alternatively comprise i.v. administering to the subject an active compound as disclosed herein. Pharmaceutical formulations and active compds. useful in the practice of the present invention are also disclosed.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:664986 CAPLUS

DOCUMENT NUMBER: 130:22621

TITLE: In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles

AUTHOR(S): Del Poeta, Maurizio; Schell, Wiley A.; Dykstra, Christine C.; Jones, Susan K.; Tidwell, Richard R.; Kumar, Arvind; Boykin, David W.; Perfect, John R.

CORPORATE SOURCE: Department of Medicine, Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, 27710, USA

SOURCE: Antimicrobial Agents and Chemotherapy (1998), 42(10), 2503-2510

CODEN: AMACQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 186953-56-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles)



10/722,085

RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA
INDEX NAME)



GI



AB Aromatic dicationic compds. possess antimicrobial activity against a wide range of eucaryotic pathogens, and in the present study an examination of the structures-functions of a series of compds. against fungi was performed. Sixty-seven dicationic mols. were screened for their inhibitory and fungicidal activities against *Candida albicans* and *Cryptococcus neoformans*. The MICs of a large number of compds. were comparable to those of the standard antifungal drugs amphotericin B and fluconazole. Unlike fluconazole, potent inhibitory compds. in this series were found to have excellent fungicidal activities. Broad-spectrum activities were observed for the carbazole I, the furan II, and the benzimidazole III. The MIC of III, one of the most potent compds., against *C. albicans* was 0.39 $\mu\text{g/mL}$, and it was the most potent compound against *C. neoformans* (MIC, ≤ 0.09 $\mu\text{g/mL}$). Selected compds. were also found to be active against *Aspergillus fumigatus*, *Fusarium solani*, *Candida* species other than *C. albicans*, and fluconazole-resistant strains of *C. albicans* and *C.*

neoformans. Since of these compds. have been safely given to animals, these classes of mols. have the potential to be developed as antifungal agents.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1997:425344 CAPLUS
 DOCUMENT NUMBER: 127:29074
 TITLE: Benzamidoxime prodrugs as antipneumocystic agents.
 INVENTOR(S): Hall, James Edwin; Tidwell, Richard Ray; Boykin, David Withers
 PATENT ASSIGNEE(S): University of North Carolina At Chapel Hill, USA; Georgia State University
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9717949	A1	19970522	WO 1996-US18496	19961115
W: AU, CA, IL, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5723495	A	19980303	US 1995-558716	19951116
CA 2237650	AA	19970522	CA 1996-2237650	19961115
AU 9711605	A1	19970605	AU 1997-11605	19961115
EP 861071	A1	19980902	EP 1996-942773	19961115
R: CH, DE, ES, FR, GB, IT, LI				
JP 2000500469	T2	20000118	JP 1997-519146	19961115
AU 764937	B2	20030904	AU 2000-62473	20001004
PRIORITY APPLN. INFO.:			US 1995-558716	A 19951116
			AU 1997-11605	A3 19961115
			WO 1996-US18496	W 19961115


OTHER SOURCE(S): MARPAT 127:29074

IT 186953-55-9P 186953-56-0P 186953-57-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (benzamidoxime prodrugs as antipneumocystic agents.)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)




RN 186953-56-0 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA INDEX NAME)



RN 186953-57-1 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-ethoxy- (9CI) (CA INDEX NAME)



AB A method of treating *Pneumocystis carinii* pneumonia in a subject in need of such treatment is disclosed. The method comprises orally administering to the subject a bis-benzamidoxime, or a pharmaceutically acceptable salt thereof, that is reduced in the subject to produce a benzamidine having anti-*P. carinii* activity. The method of the present invention may alternatively comprise i.v. administering to the subject an active compound as disclosed herein. Pharmaceutical formulations and active compounds useful in the practice of the present invention are also disclosed. E.g., the compounds were **prepared** by reaction of 1,5-dibromopentane or 1,3-dibromopentane with the appropriate 4-hydroxybenzonitrile.

L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:49577 CAPLUS

DOCUMENT NUMBER: 126:152419

TITLE: Anti-pneumocystis activity of bisamidoximes and bis-O-alkylamidoximes prodrugs

AUTHOR(S): Boykin, David W.; Kumar, Arvind; Hall, James E.; Bender, Brendan C.; Tidwell, Richard R.

CORPORATE SOURCE: Department Chemistry Center Biotechnology Drug Design, Georgia State University, Atlanta, GA, 30303, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(24), 3017-3020

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 186953-55-9P 186953-56-0P 186953-57-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-pneumocystis activity of bisamidoximes and bisalkylamidoximes prodrugs)


RN 186953-55-9 CAPLUS

CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)


10/722,085



RN 186953-56-0 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-methoxy- (9CI) (CA INDEX NAME)



RN 186953-57-1 CAPLUS
CN Benzenecarboximidamide, 4,4'-(2,5-furandiyl)bis[N-ethoxy- (9CI) (CA INDEX NAME)



AB The authors report the **synthesis** of 2,5-bis-[4-amidinophenyl]furan bisamidoxime, the corresponding bis-O-methylamidoxime and bis-O-ethylamidoxime and their evaluation as prodrugs against *Pneumocystis carinii* pneumonia.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
88.40	244.87

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-11.20	-11.20

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:54:56 ON 23 NOV 2004